Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia

BACKGROUND: Expression of Bcr-Abl in hematopoietic stem cells is sufficient to cause chronic myeloid leukemia (CML) and tyrosine kinase inhibitors (TKI) induce molecular remission in the majority of CML patients. However, the disease driving stem cell population is not fully targeted by TKI therapy,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Herrmann, Oliver, Kuepper, Maja Kim, Bütow, Marlena, Costa, Ivan G., Appelmann, Iris, Beier, Fabian, Luedde, Tom, Braunschweig, Till, Koschmieder, Steffen, Brümmendorf, Tim H., Schemionek, Mirle
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6610865/
https://ncbi.nlm.nih.gov/pubmed/31272418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5871-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados